Cardio-Phoenix recently announced that it received CE Mark approval for its Cardio-Heart heart disease diagnostic device.
European approval came in October for the “Chart” system which combines a device for capturing the heart’s physiological bio-signals with a cloud-based, AI-powered diagnostic analysis engine, according to a news release.
Cardio-Phoenix said the system is designed to ensure high levels of cardiac diagnostic effectiveness while transforming primary care into “the new front line of heart care.”
Chart is capable of detecting and diagnosing 95% of all significant and common heart diseases by prevalence, while standard electrocardiographs detect and diagnose about 44%, the company said. The difference is supplemented by the telemedicine capabilities with Chart, which is timely during the COVID-19 pandemic.
